Condition: Early-Onset Alzheimer Disease · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.
This description comes directly from the study's public registry record.
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | La Jolla, California, United States | Completed |
| Clinical Trial Site | Indianapolis, Indiana, United States | Recruiting |
| Clinical Trial Site | Montreal, Canada | Recruiting |
| Clinical Trial Site | Toronto, Canada | Recruiting |
| Clinical Trial Site | Amsterdam, Netherlands | Recruiting |
| Clinical Trial Site | Groningen, Netherlands | Completed |
| Clinical Trial Site | Huntley Street, United Kingdom | Recruiting |
| Clinical Trial Site | Sheffield, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05231785